Full Breakdown
Procter & Gamble to Acquire Thorne in $3.8 Billion Deal
8/5/2026, 4:40:47 AM
Background: Expanding Into Health and Wellness
Procter & Gamble (NYSE: PG) has been broadening its portfolio beyond traditional consumer goods into the health-and-wellness sector. Its existing supplements brands include Metamucil, Align Probiotic and New Chapter vitamins, which sit alongside oral-care and cold-relief products such as Oral-B and Vicks. The move follows a recent forecast of slower overall sales growth, even as the company’s beauty and wellness division posted strong results driven by consumer willingness to spend on discretionary self-care items.
Deal Details and Financial Metrics
On August 4, P&G announced a $3.8 billion acquisition of Thorne, a Summerville, S.C.–based supplements maker. Thorne’s annual revenue exceeded $500 million in 2025, and the company was valued at up to $4 billion in a June Financial Times report. Earlier transactions provide context: Thorne went public in late 2021 at a $525 million valuation, and private-equity firm L Catterton took it private in 2023 for $680 million. The acquisition will add Thorne’s product line to P&G’s growing self-care, prevention and personalized-wellness offerings.
Official Statements & Responses
The company did not disclose further terms at the time of the announcement.
Verbatim Quotes
- “What I can say is the price is a good price for the growth rates they have. It's kind of in line with the industry benchmarks we've seen,” — Shailesh Jejurikar, CEO
- “We are really happy with the asset itself,” — Shailesh Jejurikar, CEO
These statements from CEO Shailesh Jejurikar underscore the perceived strategic fit and pricing rationale behind the deal.
The acquisition positions P&G to deepen its foothold in the fast-growing supplements market, aligning the consumer-goods giant with sustained demand for preventive health products.
